Day: August 13, 2024

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended June 30, 2024, and provided a clinical and business update. “Cingulate has achieved major development milestones in the second quarter of 2024 relating to our first product candidate, CTx-1301 for the treatment of ADHD. The combination of the Food and Drug Administration (FDA) clearance for filing for marketing approval and completion of the registration batches keeps...

IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent HighlightsOn May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the “Merger”). The Merger is expected to create a Nasdaq-listed, clinical stage biopharmaceutical company focused on advancing OnKure’s portfolio of precision oncology therapies. The Merger and a concurrent $65 million private investment in public equity (PIPE) financing are expected to close in the second half of 2024, subject to receipt...

Solid results driven by strong revenue MISSISSAUGA, Ontario, Aug. 13, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q2 2024 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.7% interest in Kruger Products. Kruger Products Q2 2024 Business and Financial HighlightsRevenue was $509.8 million in Q2 2024 compared to $466.3 million in Q2 2023, an increase of $43.5 million or 9.3%. Adjusted EBITDA1 was $65.3 million in...

Second quarter revenue grew 33.9% year-over-year to $135.5 million Net loss driven entirely by one-time items; Adjusted EBITDA1 of $4 million BETHESDA, Md., Aug. 13, 2024 (GLOBE NEWSWIRE) — iLearningEngines, Inc. (NASDAQ: AILE) (“iLearningEngines”, “ILE”, or “the Company”), a leader in AI-powered learning and work automation for enterprises, today announced financial results for the second quarter ended June 30, 2024. “We are pleased to report financial results for our first quarter as a publicly traded company,” said Harish Chidambaran, Chief Executive Officer of iLearningEngines. “We delivered 33.9% year-over-year top line revenue growth, including $521 million of annual recurring revenue, up 33% year-over-year. It was an exciting and monumental quarter for the Company as we completed our business combination with Arrowroot Acquisition...

Achieved Record Revenue of €278 Million, Up 29% Year-over-YearGenerated Strong Cash Flow from Operating ActivitiesFurther Raising 2024 Outlook for Revenue and Adjusted EBITDA ST. GALLEN, Switzerland, Aug. 13, 2024 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its second quarter ended June 30, 2024. Carsten Koerl, Chief Executive Officer of Sportradar, said: “Our strong second quarter results, including another quarter of record revenues are a testament to the operating momentum we are generating across our business and the clear execution against our strategies to drive outperformance versus the market. We delivered robust growth across our...

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonistsInitiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)SerpinPC registrational program for the treatment of hemophilia B progressing; PRESent-2 Part 1 interim analysis planned for 2024BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are...

Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On track to report readouts from Mural’s lead asset, nemvaleukin alfa, in two late-stage clinical trials in 1H 2025 Presented clinical data from ARTISTRY-3 on less frequent dosing of nemvaleukin at the American Society of Clinical Oncology annual meeting in June; newly recommended phase 2 dose is already in the clinic in ARTISTRY-6, with preliminary readouts expected in 2025 Candidate nominations for Mural’s IL-18 and IL-12 programs are expected later this year, further deepening the company’s pipeline WALTHAM, Mass and DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing...

• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24  • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE’24  • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and provided corporate updates. “Over the past quarter, we’ve made significant strides to advance our pipeline, with key updates from our VLS-01...

Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025 Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN); data from SCCHN cohort has been accepted for poster presentation at the European Society for Medical Oncology (ESMO 2024) congress; abstract with data from NSCLC cohort has been submitted for poster presentation at an upcoming...

WILLIAMSBURG, Va., Aug. 13, 2024 (GLOBE NEWSWIRE) —  Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the second quarter ended June 30, 2024. The Company’s results include the following*:  Three Months Ended     Six Months Ended    June 30, 2024     June 30, 2023     June 30, 2024     June 30, 2023    ($ in thousands except per share data)     ($ in thousands except per share data)  Total revenue $ 50,694     $ 49,017     $ 97,243     $ 92,509  Net income attributable to common stockholders   2,622       3,133       1,962       2,551                         EBITDA   14,292       14,103       25,076       24,051  Hotel EBITDA   15,698       14,842       28,058       26,921                         FFO...